After it's 10-day run to $10, CYDY did not hold expected support at $4.6. That turned out to be just A wave in ABC correction to $2.8 on unexpected FDA-imposed delay in HIV Combo BLA application. That was our most glaring miss in this series of CYDY projections. At least we see strong A=C proportionality suggesting the correction completed Monday the 13th: A=$10-$4.6=5.4 and C=$8-$2.86=5.14, though perfect proportionality would have taken price down to $2.6
CEO Nader said on Friday that data from Phase II mild/moderate COVID blind trial of 87 patients on leronlimab had been entered and locked but will take a few days to analyze. Assuming: 1) results are released late this week or early next, and 2) results are sufficiently positive to cause widespread speculation about FDA emergency approval in August, Here's a bullish fractal path resuming strong share price growth at the pace set by the parabolic run to $10 -- which may have been just wave 1 of III towards $16-20.
It's not possible to create this projection from chart technicals alone -- we're combining the expected timing and bullish bias of upcoming news events with experience of how bullish fractal patterns evolve. Take this with a grain of salt -- if results are weaker than expected price may yet retest $2.6. On the other hand, none of us has seen how traders react to solid evidence of a highly effective treatment for an 8-month old worldwide pandemic. There could be crazy spikes into much higher double digits.